201 related articles for article (PubMed ID: 31257085)
1. Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
Zhao L; Sun N; Tian L; Zhao S; Sun B; Sun Y; Zhao D
Bioorg Med Chem Lett; 2019 Aug; 29(16):2016-2024. PubMed ID: 31257085
[TBL] [Abstract][Full Text] [Related]
2. Structure-based ligand design to overcome CYP inhibition in drug discovery projects.
Brändén G; Sjögren T; Schnecke V; Xue Y
Drug Discov Today; 2014 Jul; 19(7):905-11. PubMed ID: 24642031
[TBL] [Abstract][Full Text] [Related]
3. Selective Targeting of Heme Protein in Cytochrome P450 and Nitric Oxide Synthase by Diphenyleneiodonium.
Szilagyi JT; Mishin V; Heck DE; Jan YH; Aleksunes LM; Richardson JR; Heindel ND; Laskin DL; Laskin JD
Toxicol Sci; 2016 May; 151(1):150-9. PubMed ID: 26880746
[TBL] [Abstract][Full Text] [Related]
4. Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.
Sridhar J; Liu J; Foroozesh M; Stevens CL
Molecules; 2012 Aug; 17(8):9283-305. PubMed ID: 22864238
[TBL] [Abstract][Full Text] [Related]
5. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
6. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
[TBL] [Abstract][Full Text] [Related]
7. Computational prediction of cytochrome P450 inhibition and induction.
Kato H
Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450.
Špičáková A; Kraus P; Gucký T; Kryštof V; Strnad M; Bazgier V; Otyepka M; Kubíčková V; Poruba M; Rácová Z; Zapletalová I; Anzenbacher P
Physiol Res; 2020 Dec; 69(Suppl 4):S627-S636. PubMed ID: 33646005
[TBL] [Abstract][Full Text] [Related]
9. Conservation analysis of class-specific positions in cytochrome P450 monooxygenases: functional and structural relevance.
Gricman Ł; Vogel C; Pleiss J
Proteins; 2014 Mar; 82(3):491-504. PubMed ID: 24105833
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.
Havrylyuk D; Heidary DK; Glazer EC
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672458
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
Dinger J; Meyer MR; Maurer HH
Anal Bioanal Chem; 2014 Jul; 406(18):4453-64. PubMed ID: 24830396
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
14. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
15. Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.
Korzekwa K
Methods Mol Biol; 2021; 2342():237-256. PubMed ID: 34272697
[TBL] [Abstract][Full Text] [Related]
16. CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes.
Plonka W; Stork C; Šícho M; Kirchmair J
Bioorg Med Chem; 2021 Sep; 46():116388. PubMed ID: 34488021
[TBL] [Abstract][Full Text] [Related]
17. Cytochromes P450 and drug discovery.
Lamb DC; Waterman MR; Kelly SL; Guengerich FP
Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
[TBL] [Abstract][Full Text] [Related]
18. Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes.
Juvonen RO; Ahinko M; Huuskonen J; Raunio H; Pentikäinen OT
Xenobiotica; 2019 Sep; 49(9):1015-1024. PubMed ID: 30272491
[TBL] [Abstract][Full Text] [Related]
19. Structural modelling of the human drug-metabolizing cytochromes P450.
Lewis DF; Ito Y; Goldfarb PS
Curr Med Chem; 2006; 13(22):2645-52. PubMed ID: 17017916
[TBL] [Abstract][Full Text] [Related]
20. Molecular Docking as a Promising Predictive Model for Silver Nanoparticle-Mediated Inhibition of Cytochrome P450 Enzymes.
Wasukan N; Kuno M; Maniratanachote R
J Chem Inf Model; 2019 Dec; 59(12):5126-5134. PubMed ID: 31714078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
